| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3930909 | European Urology Supplements | 2008 | 5 Pages |
Abstract
The case studies reported in this paper confirm the effectiveness of sunitinib for the treatment of patients with mRCC stratified into different risk groups, with manageable adverse events. There is a need for additional stratification tools and new definitions for tumor responses for the new targeted therapies.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Vincenzo Ficarra, Antonio Galfano, Marco Cosentino, Manfred Johannsen,